{
  "@context": "aku-v2",
  "@type": "pharmacology",
  "@id": "vasc:pharmacology:pharm-003-rivaroxaban",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T02:55:00.000Z",
    "updated": "2026-01-07T02:55:00.000Z",
    "contributors": [
      "vascular-surgery-agent"
    ],
    "confidence": 0.93,
    "status": "enhanced",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology/anticoagulation",
    "type": "pharmacology",
    "difficulty": "intermediate",
    "importance": "core"
  },
  "content": {
    "title": "Rivaroxaban in Vascular Disease",
    "description": "Direct oral anticoagulant (DOAC) with direct factor Xa inhibition, increasingly used in PAD and post-revascularization settings.",
    "mechanism": "Direct competitive inhibition of factor Xa (free and clot-bound), no antithrombin required",
    "pharmacokinetics": {
      "bioavailability": "80-100% (with food for higher doses)",
      "half_life": "5-9 hours in healthy adults, longer in elderly/renal impairment",
      "elimination": "1/3 renal, 2/3 hepatobiliary"
    },
    "vascular_surgery_applications": {
      "compass_trial": {
        "regimen": "Rivaroxaban 2.5mg BID + aspirin 100mg daily",
        "population": "Stable CAD and/or PAD",
        "results": "Reduced MACE and MALE, increased bleeding"
      },
      "post_revascularization": "Emerging evidence for use after peripheral intervention",
      "dvt_vte": "Standard indication"
    },
    "dosing": {
      "pad_compass": "2.5mg twice daily (with aspirin)",
      "vte_treatment": "15mg BID x 21 days, then 20mg daily",
      "vte_prevention": "10mg daily"
    },
    "perioperative_management": {
      "hold": "24-48 hours before procedure (CrCl dependent)",
      "restart": "24-48 hours after if hemostasis adequate",
      "bridging": "Generally not required"
    },
    "reversal": {
      "andexanet_alfa": "Specific reversal agent",
      "pcc": "4-factor PCC can be used if andexanet unavailable"
    },
    "statement": "Rivaroxaban in Vascular Disease is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pharmacology Anticoagulation that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Rivaroxaban in Vascular Disease helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Rivaroxaban in Vascular Disease include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Rivaroxaban in Vascular Disease."
    }
  },
  "relationships": {
    "related_to": [
      "vasc:pharmacology:aspirin",
      "vasc:pad:medical-therapy"
    ],
    "evidence_from": [
      "vasc:trials:compass"
    ]
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). Rivaroxaban in Vascular Disease. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  }
}